Book Review: Transhumanist Dreams and Dystopian Nightmares
By John Galloway,
BioNews
| 03. 11. 2013
Perhaps fortuitously, I started to read
Maxwell Mehlman's
book at the same time as
Roy Porter's 'A Short History of Madness'. It was then difficult not to muse on what
Jonathan Swift might have made of 'transhumanising scientists'. His satirising of scientists 'infected with lunacy' in the eighteenth century provides a hard to avoid parallel with Mehlman's very much not satirical account of biologists of the twentieth century.
Every school child now knows that molecular genetics is set to transform the world as we know it. Although exactly who 'we' are, is not specified; nor are we always told whether the transformation will be for good or ill. We can be reasonably certain though that most of the world's existing population will be dead before genetics' claims for medicine have any effect on them.
Read more...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...